Germantown, WI (July 9)—
Cambridge Major Laboratories
appointed James Davidson as chief operating officer. In this role, he will be responsible for all technical operations, providing
technical and strategic oversight to all chemistry, engineering, and quality functions within the organization. Prior to joining
CML, Jim Davidson spent 23 years in the pharmaceutical industry with Parke-Davis/Warner-Lambert and Pfizer, most recently
as vice-president of science and technology within the pharmaceutical sciences division of Pfizer. In this role, he managed
groups located in Michigan, Missouri and California and was responsible for all aspects of the chemical (API), analytical,
and pharmaceutical dosage-form development across a significant portion of Pfizer's research portfolio.
Albany, NY (July 2)—
Albany Molecular Research, Inc. (AMRI) gave Prasad S. Raje leadership responsibility for AMRI's manufacturing business in India. He transferred from Syracuse,
New York to company offices in Mumbai, India and will report to Jonathan Evans, AMRI vice-president for pharmaceutical development
Cambridge, MA (June 29)—
reported that Peter Kellogg, executive vice-president, finance and chief financial officer (CFO) will leave the organization
to become CFO at
Merck & Co., Inc.
(Whitehouse Station, NJ). Kellogg will leave Biogen Idec on Aug. 10. The company will announce its plans regarding the CFO
position over the coming weeks.
Cambridge, MA (June 26)—Lisa Everen joined
Merrimack Pharmaceuticals, Inc.
as senior vice-president and chief financial officer. Everen was previously vice-president and treasurer of Amgen, Inc.
South Plainfield, NJ (June 26)—
PTC Therapeutics, Inc.
appointed Manal Morsy, MD, PhD, vice-president of regulatory affairs. In this capacity, Morsy will lead PTC's regulatory affairs
activities. Morsy joins the company after spending three years at Tibotec/J&J, most recently as senior director of global
Stamford, CT (June 25)—
Purdue Pharma L.P.
named John H. Stewart acting president, effective June 11, 2007. Currently President of Purdue Pharma, Canada, an independent
associated company, Stewart succeeds Michael Friedman who retired as president and CEO.
Houston, TX (June 25)—
Encysive Pharmaceuticals, Inc.
promoted George W. Cole to president and CEO. Cole has served as the company' s chief operating officer since November 2005.
He previously was president of Altana Pharma US.
Richmond, VA (June 25)—
named Steve Glover president of the company's newly formed follow-on biologics business. Glover will lead the development
of Insmed's follow-on biologics capability and its portfolio of biogeneric and biosimilar products. He previously served as
senior vice-president and general manager at Andrx Laboratories and Andrx Therapeutics. He also has held multiple roles at
Hoffman LaRoche, Amgen, and IMS Health.
East Windsor, NJ (June 20)—
promoted Vivian Liu to chief executive officer. Liu succeeds Richard J. Berman, who served as CEO since January 2006. Liu
joined the company in 1994 and was appointed executive vice-president and chief operating officer in June 2006.
Berkeley, CA (June 20)—Gary C. Visor, PhD, was named vice-president of pharmaceutics at
In this capacity, he will be responsible for managing pharmaceutical drug-substance scale-up, manufacturing, and dosage design
and development. He previously held positions with OSI Pharmaceuticals, Cardinal Helath, InterMune, Roche Bioscience, and
London (June 19)—
The European Medicines Agency 's
Committee for Medicinal Products for Human Use (CHMP) elected Eric Abadie chair and Tomas Salmonson vice-chair. Both will
serve three-year terms. Abadie and Salmonson have been members of CHMP since its formation in 2004, and they also were members
of CHMP's predecessor, the Committee for Proprietary Medicinal Products.
Bloomington, IN (June 18)—
promoted two employees to vice-president. Connie Degan was appointed vice-president of operations, and Tedd Green was named
vice-president of business operations and chief financial officer. Degan has held numerous quality and manufacturing positions.
She most recently worked as quality director for Baxter Pharmaceutical Solutions. She joined Cook as director of quality in
2004 and assumed responsibility for the manufacturing group as director of operations. Green joined Cook in 2005 after serving
as a senior business analyst for Eli Lilly & Company.
Petaluma, CA (June 18)—
Oculus Innovative Sciences, Inc.
named Dana Redhair vice-president of regulatory affairs and quality. Redhair joins the company after serving in a similar
capacity at SGX Pharmaceuticals. He has held regulatory affairs roles at Elan Pharmaceuticals, Chiron Corporation, Berlex
Labs, Genentech, and UCSF Cancer Research Institute.
South San Francisco, CA (June 18)—
appointed Michael S. Eison, PhD, vice-president of regulatory affairs. Eison most recently served as vice-president of research
and development for the Palo Alto site of Stiefel Laboratories. He also held regulatory positions with InterMune and Connetics.
—Chris Waddick was promoted to president and chief executive officer of Vasogen Inc. Waddick joined the company in 1995 and
most recently served as chief operating officer and chief financial officer.
Cincinnati, OH (June 15)—
appointed Paul Roney, PhD, and Lisa Jenkins, PhD, senior regulatory consultants. Before joining Kendle, Roney was a toxicology
reviewer in the Division of Neurology Products at the US Food and Drug Administration. Jenkins joins the company after serving
as senior manager of worldwide regulatory affairs at Wyeth Pharmaceuticals, Inc.
Ames, IA (June 15)—
BioForce Nanosciences Holdings, Inc.
named Kerry Frey president and Gregory Brown executive vice-president. Both will continue to hold their former positions of
chief operating officer and chief financial officer, respectively.